Kaempferol inhibits the growth and metastasis of cholangiocarcinoma in vitro and in vivo

Acta Biochimica et Biophysica Sinica

Volumn 48, Issue 3, 2015, Pages 238-245

  Qin, Youyou ^a   Cui, Wu ^a   Yang, Xuewei ^a   Tong, Baifeng ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

cholangiocarcinoma; invasion; kaempferol; proliferation

Indexed keywords

KAEMPFEROL; KAEMPFEROL DERIVATIVE;

ANIMAL; BAGG ALBINO MOUSE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; IN VITRO STUDY; MALE; MOUSE; NEOPLASM METASTASIS; PATHOLOGY; PREVENTION AND CONTROL; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BILE DUCT NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; HUMANS; IN VITRO TECHNIQUES; KAEMPFEROLS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS;

EID: 84960131606     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmv133     Document Type: Article

References (45)

1. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013, 145: 1215-1229.
2. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang Y, Wiangnon S, et al. Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma-focus on East and South-Eastern Asia. Asian Pac J Cancer Prev 2010, 11: 1159-1166.
3. Srivatanakul P, Parkin DM, Jiang YZ, Khlat M, Kao-Ian UT, Sontipong S, Wild C. The role of infection by Opisthorchis viverrini, hepatitis B virus, and aflatoxin exposure in the etiology of liver cancer in Thailand. A correlation study. Cancer 1991, 68: 2411-2417.
4. Hammill CW, Wong LL. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg 2008, 207: 594-603.
5. Al-Bahrani R, Abuetabh Y, Zeitouni N, Sergi C. Cholangiocarcinoma: risk factors, environmental influences and oncogenesis. Ann Clin Lab Sci 2013, 43: 195-210.
6. Shaib YH, Davila JA, Henderson L, McGlynn KA, El-Serag HB. Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the United States: a population-based study. J Clin Gastroenterol 2007, 41: 911-917.
7. Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol 2008, 14: 6458-6466.
8. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012, 61: 1657-1669.
9. Somerset SM, Johannot L. Dietary flavonoid sources in Australian adults. Nutr Cancer 2008, 60: 442-449.
10. Rice-Evans C. Flavonoid antioxidants. Curr Med Chem 2001, 8: 797-807.
11. Kowalski J, Samojedny A, Paul M, Pietsz G, Wilczok T. Effect of apigenin, kaempferol and resveratrol on the expression of interleukin-1beta and tumor necrosis factor-alpha genes in J774.2 macrophages. Pharmacol Rep 2005, 57: 390-394.
12. Chen AY, Chen YC. A review of the dietary flavonoid, kaempferol on human health and cancer chemoprevention. Food Chem 2013, 138: 2099-2107.
13. Bobe G, Weinstein SJ, Albanes D, Hirvonen T, Ashby J, Taylor PR, Virtamo J, et al. Flavonoid intake and risk of pancreatic cancer in male smokers (Finland). Cancer Epidemiol Biomarkers Prevent 2008, 17: 553-562.
14. Cui Y, Morgenstern H, Greenland S, Tashkin DP, Mao JT, Cai L, Cozen W, et al. Dietary flavonoid intake and lung cancer-a population-based casecontrol study. Cancer 2008, 112: 2241-2248.
15. Song W, Dang Q, Xu D, Chen Y, Zhu G, Wu K, Zeng J, et al. Kaempferol induces cell cycle arrest and apoptosis in renal cell carcinoma through EGFR/p38 signaling. Oncol Rep 2014, 31: 1350-1356.
16. Choi EJ, Ahn WS. Kaempferol induced the apoptosis via cell cycle arrest in human breast cancer MDA-MB-453 cells. Nutr Res Pract 2008, 2: 322-325.
17. Song H, Bao J, Wei Y, Chen Y, Mao X, Li J, Yang Z, et al. Kaempferol inhibits gastric cancer tumor growth: an in vitro and in vivo study. Oncol Rep 2015, 33: 868-874.
18. Yoshida T, Konishi M, Horinaka M, Yasuda T, Goda AE, Taniguchi H, Yano K, et al. Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis. Biochem Biophys Res Commun 2008, 375: 129-133.
19. Mylonis I, Lakka A, Tsakalof A, Simos G. The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions. Biochem Biophys Res Commun 2010, 398: 74-78.
20. Leardkamolkarn V, Tiamyuyen S, Sripanidkulchai BO. Pharmacological activity of Kaempferia parviflora extract against human bile duct cancer cell lines. Asian Pac J Cancer Prev 2009, 10: 695-698.
21. Lee KM, Lee DE, Seo SK, Hwang MK, Heo YS, Lee KW, Lee HJ. Phosphatidylinositol 3-kinase, a novel target molecule for the inhibitory effects of kaempferol on neoplastic cell transformation. Carcinogenesis 2010, 31: 1338-1343.
22. Phromnoi K, Yodkeeree S, Anuchapreeda S, Limtrakul P. Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids. Acta Pharmacol Sin 2009, 30: 1169-1176.
23. Susnow N, Zeng L, Margineantu D, Hockenbery DM. Bcl-2 family proteins as regulators of oxidative stress. Semin Cancer Biol 2009, 19: 42-49.
24. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005, 366: 1303-1314.
25. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006, 3: 33-42.
26. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008, 48: 308-321.
27. Khan SA, Miras A, Pelling M, Taylor-Robinson SD. Cholangiocarcinoma and its management. Gut 2007, 56: 1755-1756.
28. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005, 16(Suppl. 2): ii93-ii96.
29. Briggs CD, Neal CP, Mann CD, Steward WP, Manson MM, Berry DP. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer 2009, 45: 33-47.
30. Luo H, Rankin GO, Li Z, Depriest L, Chen YC. Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway. Food Chem 2011, 128: 513-519.
31. Labbe D, Provencal M, Lamy S, Boivin D, Gingras D, Beliveau R. The flavonols quercetin, kaempferol, and myricetin inhibit hepatocyte growth factor-induced medulloblastoma cell migration. J Nutr 2009, 139: 646-652.
32. Li C, Zhao Y, Yang D, Yu Y, Guo H, Zhao Z, Zhang B, et al. Inhibitory effects of kaempferol on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-9. Biochem Cell Biol 2015, 93: 16-27.
33. Lin CW, Chen PN, Chen MK, Yang WE, Tang CH, Yang SF, Hsieh YS. Kaempferol reduces matrix metalloproteinase-2 expression by downregulating ERK1/2 and the activator protein-1 signaling pathways in oral cancer cells. PLoS One 2013, 8: e80883.
34. Chen HJ, Lin CM, Lee CY, Shih NC, Peng SF, Tsuzuki M, Amagaya S, et al. Kaempferol suppresses cell metastasis via inhibition of the ERK-p38-JNK and AP-1 signaling pathways in U-2 OS human osteosarcoma cells. Oncol Rep 2013, 30: 925-932.
35. Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol 2015, 44-46C: 94-112.
36. Shirabe K, Shimada M, Kajiyama K, Hasegawa H, Gion T, Ikeda Y, Takenaka K, et al. Expression of matrix metalloproteinase-9 in surgically resected intrahepatic cholangiocarcinoma. Surgery 1999, 126: 842-846.
37. Blain EJ. Mechanical regulation of matrix metalloproteinases. Front Biosci 2007, 12: 507-527.
38. Ehrenfeld P, Conejeros I, Pavicic MF, Matus CE, Gonzalez CB, Quest AF, Bhoola KD, et al. Activation of kinin B1 receptor increases the release of metalloproteases-2 and -9 from both estrogen-sensitive and -insensitive breast cancer cells. Cancer Lett 2011, 301: 106-118.
39. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115: 3719-3727.
40. Huang WW, Tsai SC, Peng SF, Lin MW, Chiang JH, Chiu YJ, Fushiya S, et al. Kaempferol induces autophagy through AMPK and AKT signaling molecules and causes G2/M arrest via downregulation of CDK1/cyclin B in SK-HEP-1 human hepatic cancer cells. Int J Oncol 2013, 42: 2069-2077.
41. Xie F, Su M, Qiu W, Zhang M, Guo Z, Su B, Liu J, et al. Kaempferol promotes apoptosis in human bladder cancer cells by inducing the tumor suppressor, PTEN. Int J Mol Sci 2013, 14: 21215-21226.
42. Leelawat K, Leelawat S, Narong S, Hongeng S. Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J Gastroenterol 2007, 13: 1561-1568.
43. Tanno S, Yanagawa N, Habiro A, Koizumi K, Nakano Y, Osanai M, Mizukami Y, et al. Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Res 2004, 64: 3486-3490.
44. Al-Bahrani R, Tuertcher D, Zailaie S, Abuetabh Y, Nagamori S, Zetouni N, Bahitham W, et al. Differential SIRT1 expression in hepatocellular carcinomas and cholangiocarcinoma of the liver. Ann Clin Lab Sci 2015, 45: 3-9.
45. Johnston J, Al-Bahrani R, Abuetabh Y, Chiu B, Forsman CL, Nagamori S, Leng R, et al. Twisted gastrulation expression in cholangiocellular and hepatocellular carcinoma. J Clin Pathol 2012, 65: 945-948.